Review your health goals, medical history, and current medications with our medical team to determine the right peptide protocol.
Baseline blood work and health screening to establish safe starting parameters and identify any contraindications.
Your personalized peptide protocol is designed based on your labs, goals, and health profile. Training on self-administration provided.
Regular follow-up appointments and lab work to track progress, adjust dosing, and ensure optimal results.
IDEAL FOR
PT-141 may be appropriate for individuals experiencing low sexual desire:
Women with HSDD
Premenopausal women experiencing persistent low sexual desire that causes personal distress (FDA-approved indication).
Men with Libido Concerns
Men experiencing decreased sexual desire not fully addressed by other treatments (off-label use).
Those Seeking Alternatives
Individuals who haven’t responded adequately to other approaches or prefer a different mechanism of action.
Individuals with uncontrolled high blood pressure, cardiovascular disease, or those taking medications that significantly affect blood pressure. PT-141 may cause temporary blood pressure increases. Health screening is required.
PT-141 (Bremelanotide), marketed as Vyleesi, is an FDA-approved peptide for treating hypoactive sexual desire disorder (HSDD) in premenopausal women. Unlike medications that work on blood flow alone, PT-141 acts on the central nervous system—specifically melanocortin receptors in the hypothalamus—to address the brain’s role in sexual desire and arousal.
This represents a fundamentally different approach to sexual wellness, targeting desire at its neurological source. PT-141 is the first and only centrally-acting, FDA-approved treatment for low sexual desire in women.
PT-141 is also used off-label for libido concerns in men, where early clinical experience suggests potential benefits for desire and erectile function.
Click on a question to see more
PT-141 activates melanocortin receptors (MC3R and MC4R) in the hypothalamus, the brain region involved in sexual arousal and desire. Unlike Viagra or Cialis which work on blood flow, PT-141 addresses desire at its neurological source.
The FDA-approved dosing is subcutaneous injection at least 45 minutes before anticipated sexual activity. Nasal spray options are also available through compounding pharmacies. Maximum recommended use is 8 doses per month.
The most common side effect is nausea (approximately 40% of patients), which is usually mild and temporary. Flushing and headache may also occur. PT-141 can cause temporary blood pressure increases, which is why cardiovascular screening is required.
Yes. PT-141 (marketed as Vyleesi) received FDA approval in June 2019 for treating HSDD in premenopausal women. It is the only FDA-approved treatment of its kind. Use in men is off-label.
Absolutely. All consultations and treatments at Cienega Medical are completely confidential. We understand the sensitive nature of sexual wellness concerns and provide a discreet, judgment-free environment.
RNs, NPs, PAs, and licensed specialists with 10+ years average experience
Dr Neal Kumar
Dermatologist + Medical Director
Brittany
Medical Liaison
Mary
Registered Nurse + Director of Training
Natalie
Registered Nurse
Christopher
Medical Liaison
Katelyn
Medical Liaison
Mariah
Medical Assistant
Laura
Medical Liaison
Yasmin
Physician Assistant
Rose
Medical Liaison
Maggie
Registered Nurse
Jasmine
Licensed Esthetician
Eric
Physician Assistant
Joanna
Nurse Practitioner
Cheyenne
Licensed Esthetician
Lusine
Nurse Practitioner
Shrabya
Nurse Practitioner
Stephanie
Nurse Practitioner
See real-time availability · Pick your time instantly
Serving LA since 2010 · 3,250+ five-star reviews
Questions? Call us at (323) 655-8220
Book a Confidential Consultation